Human Polycomb group EED protein negatively affects HIV-1 assembly and release by Rakotobe, Dina et al.
BioMed  Central
Page 1 of 19
(page number not for citation purposes)
Retrovirology
Open Access Research
Human Polycomb group EED protein negatively affects HIV-1 
assembly and release
Dina Rakotobe1, Jean-Claude Tardy1,2, Patrice André2, Saw See Hong1, Jean-
Luc Darlix3 and Pierre Boulanger*1,4
Address: 1Laboratoire de Virologie & Pathologie Humaine, Université Lyon I & CNRS FRE-3011, Faculté de Médecine Laennec, 7, rue Guillaume 
Paradin, 69372 Lyon Cedex 08, France, 2Laboratoire de Virologie Médicale-Nord, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, 103, 
Grand'Rue de la Croix-Rousse, 69317 Lyon Cedex 04, France, 3LaboRétro, Unité de Virologie Humaine, INSERM U-758 & IFR128 BioSciences 
Lyon-Gerland, Ecole Normale Supérieure, 46, allée d'Italie, 69364 Lyon Cedex 07, France and 4Laboratoire de Virologie Médicale, Hospices Civils 
de Lyon, CBPE, 59, Boulevard Pinel, 69677 Bron Cedex, France
Email: Dina Rakotobe - dinaraktb@yahoo.fr; Jean-Claude Tardy - jean-claude.tardy@chu-lyon.fr; Patrice André - patrice.andre@chu-lyon.fr; 
Saw See Hong - sawsee.hong@sante.univ-lyon1.fr; Jean-Luc Darlix - jldarlix@ens-lyon.fr; Pierre Boulanger* - Pierre.Boulanger@sante.univ-
lyon1.fr
* Corresponding author    
Abstract
Background: The human EED protein, a member of the superfamily of Polycomb group (PcG) proteins with WD-
40 repeats, has been found to interact with three HIV-1 components, namely the structural Gag matrix protein
(MA), the integrase enzyme (IN) and the Nef protein. The aim of the present study was to analyze the possible
biological role of EED in HIV-1 replication, using the HIV-1-based vector HIV-Luc and EED protein expressed by
DNA transfection of 293T cells.
Results: During the early phase of HIV-1 infection, a slight negative effect on virus infectivity occurred in EED-
expressing cells, which appeared to be dependent on EED-MA interaction. At late times post infection, EED
caused an important reduction of virus production, from 20- to 25-fold as determined by CAp24 immunoassay,
to 10- to 80-fold based on genomic RNA levels, and this decrease was not due to a reduction of Gag protein
synthesis. Coexpression of WTNef, or the non-N-myristoylated mutant NefG2A, restored virus yields to levels
obtained in the absence of exogenous EED protein. This effect was not observed with mutant NefΔ57 mimicking
the Nef core, or with the lipid raft-retargeted fusion protein LAT-Nef. LATAA-Nef, a mutant defective in the lipid
raft addressing function, had the same anti-EED effect as WTNef. Cell fractionation and confocal imaging showed
that, in the absence of Nef, EED mainly localized in membrane domains different from the lipid rafts. Upon co-
expression with WTNef, NefG2A or LATAA-Nef, but not with NefΔ57 or LAT-Nef, EED was found to relocate
into an insoluble fraction along with Nef protein. Electron microscopy of HIV-Luc producer cells overexpressing
EED showed significant less virus budding at the cell surface compared to control cells, and ectopic assembly and
clustering of nuclear pore complexes within the cytoplasm.
Conclusion: Our data suggested that EED exerted an antiviral activity at the late stage of HIV-1 replication,
which included genomic RNA packaging and virus assembly, resulting possibly from a mistrafficking of viral
genomic RNA (gRNA) or gRNA/Gag complex. Nef reversed the EED negative effect on virus production, a
function which required the integrity of the Nef N-terminal domain, but not its N-myristoyl group. The
antagonistic effect of Nef correlated with a cellular redistribution of both EED and Nef.
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Background
EED protein, the human ortholog of the mouse embry-
onic ectoderm development (eed) gene product, is a mem-
ber of the superfamily of WD-40 repeat proteins and
widely conserved Polycomb group (PcG) family of proteins
[1-7]. The human EED protein, also called WAIT-1 (for
WD protein associated with integrin cytoplasmic tails-1;
[8]), can interact with the cytoplasmic tail of integrin β7
subunit, a domain which is involved in major integrin
functions such as receptor affinity and signaling [9,10].
EED was also found to interact with three HIV-1 proteins,
the Gag matrix protein MA [11], the integrase enzyme IN
[12] and the Nef regulatory protein [13]. Although recog-
nized as a nuclear factor, EED has been shown to shuttle
between the nucleus and the plasma membrane [8],
where it forms a complex with HIV-1 Nef releasing an
EED-mediated transcriptional block [13]. The data
obtained with Nef and EED were consistent with the
known functions of PcG proteins, which participate in the
maintenance of the silent state of chromatin in upper
eukaryotes, such as in female X chromosome inactivation
[14], and generally act as transcriptional repressors of
homeotic genes (reviewed in [15-18]). They were also
consistent with the finding that HIV-1 preferentially inte-
grates into transcriptionally active regions of the host
genome [19-22]. Thus, regions of cellular genome unoc-
cupied by EED or EED-containing multiprotein com-
plexes might be preferred targets for proviral DNA
integration.
EED is part of multiprotein edifices called Polycomb
Repressive Complexes (PRCs) that are found in Drosophila
and in mammals [17]. Several types of PRCs have been
identified and commonly called PRC1, PRC2 and PRC3
[23]. PRC2/3 contain at least five components, EED,
EZH2, SUZ12, RbAp38 and AEBP2 [23-25]. Four isoforms
of human EED have been identified [24], due to alterna-
tive translation initiations at codons specific for Val1
(EED1), Val36 (EED2), Met95 (EED3) and Met110
(EED4), respectively, as aligned with the mouse EED
sequence of 535 residues [5,7], and not to alternative
splicing of the eed transcript, as previously hypothesized
[11]. It is generally accepted that PRC3 complex contains
the two shorter forms of EED (EED3, EED4), while PRC2
contains the longer EED1 form, and the intermediate
EED2 form is present in another distinct PRC complex
[23]. However, a more dynamic and flexible view of the
PRC composition has been proposed [17].
Because EED can interact with three major HIV-1 compo-
nents, we wanted to investigate the interplay between EED
and the virus in infected cells. We found that EED iso-
forms 3 and 4 (EED3/4) had only a moderate antiviral
activity on infecting virions, whereas at the late phase of
virus replication, EED3/4 showed a strong negative effect
on virus production. Interestingly, this effect was reversed
by WTNef, and its non-N-myristoylated mutant NefG2A,
implying that it was not dependent on Nef packaging into
virions. No anti-EED effect was observed with the N-ter-
minal deletion mutant called NefΔ57, or with LAT-Nef, a
Nef fusion protein targeted to the membrane microdo-
mains known as lipid rafts [26]. The EED antagonistic
function of Nef was associated with a cellular redistribu-
tion of EED3/4 proteins, whereby EED and Nef were
depleted from the membranes and redirected to a still
undefined compartment. EED did not inhibit Gag protein
synthesis, and our results suggested that virus assembly
and genome packaging were the major targets of the EED
inhibitory activity.
Results
Effect of EED3/4 on incoming HIV-1
The observation that isoforms 3 and 4 of EED were recov-
ered in the same PRC3 complex [23] suggested that cer-
tain biological functions probably required the EED3-
EED4 pair. In the HIV-1 context, we found that the MA
protein interacted with EED via a single site common to
shorter and longer isoforms [11], and that the IN bound
to EED via two discrete regions contained within residues
95–535, corresponding to EED3 [12]. We therefore kept
the Met-codon at position 110, which could function as a
natural alternative initiator of translation, allowing the
simultaneous expression of both EED3 (441 residues)
and EED4 (428 residues) isoforms, abbreviated EED3/4
in the present study.
In whole cell lysates from control 293T cells (Fig. 1a, lane
1 ; Fig. 1b, left half of the panel), only trace amounts of
endogenous EED were detected. In 293T cells transfected
with pTracer-EED, the expected doublet band correspond-
ing to exogenous EED3 and EED4 proteins at 52 and 51
kDa, respectively, was observed (Fig. 1a, lane 2). In kinet-
ics analysis, EED3/4 proteins were clearly accumulating at
16 h, with a maximum level at 48 h (Fig. 1b; lanes 16 h to
72 h).
To determine the possible effect of EED on incoming HIV-
Luc virions in a single-round replication assay, 293T cells
expressing EED3/4 proteins were infected by VSV-G-pseu-
dotyped HIV-Luc, and luciferase expression assayed at dif-
ferent times post-infection (pi) and at different pTracer-
EED inputs (Fig. 2a). The HIV-driven luciferase activity
was found to be at modestly but consistently lower levels
in EED3/4-expressing cells compared to control cells (Fig.
2b, c), with a maximum effect (2–3-fold) observed at 8 to
24 h pi. The negative effect of EED3/4 on HIV-Luc expres-
sion occurred in a dose-dependent manner (Fig. 2d), and
was less pronounced with the MA-binding defective
mutant EED394 (Fig. 2b, c), suggesting that this
depended, at least in part, on EED-MA interaction.Retrovirology 2007, 4:37 http://www.retrovirology.com/content/4/1/37
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Because the luc gene has been inserted into the nef region
of HIV-Luc genome, the HIV-1 virions used in the above
experiments lacked the Nef protein [27] shown to be an
EED interactor [13]. We then expressed the Nef protein in
trans in HIV-Luc-producer cells (Fig. 2a), and examined
whether Nef incorporation into virions could overcome
the negative effect of exogenous EED3/4. As expected
from previous studies [28], WTNef increased the infectiv-
ity of HIV-Luc by a factor of 2-fold at all time points, com-
pared to vector produced in the absence of Nef or in the
presence of the packaging-defective mutant NefG2A (Fig.
2e). However, the packaging-competent WTNef did not
change the negative effect of EED3/4 on HIV-Luc expres-
sion in newly infected cells (Fig. 2e).
Effect of EED3/4 on virion production
The influence of EED3/4 on virus production and infectiv-
ity was investigated as illustrated in Fig. 3a, using cells
cotransfected with pNL4-3Luc(R-E-), phCMV-G encoding
VSV-G and pTracer-EED or pTracer-Emp ('empty vector
DNA' used as control). Cell culture supernatants were har-
vested 48 h after DNA transfection, and virions recovered
and purified as described in Materials & Methods. Virion-
containing fractions were extensively characterized with
Over-expression of EED3/4 isoforms in 293T cells Figure 1
Over-expression of EED3/4 isoforms in 293T cells. (a), SDS-PAGE and radioimmunoblot analysis of soluble fraction of 
293T cell lysates after transfection with pTracer-Emp (lane 1) or pTracer-EED (lane 2) ; bacterially-expressed, histidine-tagged 
isoform 3 (EED441-H6; arrow) is shown in lane 3. (b), Kinetics of transient expression of exogenous EED3/4, using pTracer-
EED versus control empty plasmid pTracer-Emp. Autoradiograms of blots reacted with anti-EED antibody and 35SLR-labeled 
anti-rabbit IgG antibody. Note that the endogenous EED proteins were barely detectable in soluble lysates from 293T cells, 
whereas exogenous EEDs were visible as a doublet band at 52 and 51 kDa, detectable as early as 16 h after transfection with a 
maximum at 48 h.
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Antiviral effect of EED3/4 on incoming HIV-Luc virions Figure 2
Antiviral effect of EED3/4 on incoming HIV-Luc virions. (a), Experimental protocol. (b), Time-course analysis of luci-
ferase expression in 293T cells transfected with pTracer-EED, pTracer-EED394 (EED ST394AI mutant) or control pTracer-
Emp at constant plasmid input (1 μg/106 cells), and infected with HIV-Luc vector. Luciferase activity, expressed as relative light 
units (RLU), was normalized to equal protein content. (c), Ratio of luciferase levels in cells expressing EED3/4 or EED394, ver-
sus control (pTracer-Emp). (d), Dose-response analysis of EED3/4 effect on luciferase expression.(e), Effect of the coexpres-
sion of WTNef or packaging-defective mutant NefG2A on EED antiviral activity. The discrete negative effect of EED on virus 
infectivity did not change when NefWT was provided in trans to virions in producer cells.
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respect to virus infectivity based on luciferase activity in
recipient cells, and levels of virion genomic RNA, and RT
activity (Fig. 3a). Luciferase activity was reduced by about
4- to 5-fold at 96 h pi when HIV-Luc was produced by
EED3/4-expressing cells, compared to control cells (Fig.
3b).
Virion production, as monitored by CAp24-ELISA, was
found to be lower from EED3/4-cells, in comparison with
control cells (about 20-fold lower at 48 h posttransfec-
tion; Fig. 3c). Likewise, the level of virion genomic RNA
was strongly diminished (at least 30-fold less) in particles
produced by EED3/4-expressing cells in comparison with
control samples at 16 to 48 h posttransfection (Fig. 3d).
The mean density value and Gag protein composition of
virions did not change upon EED expression in HIV-1
producer cells (Fig. 3e). Virions were also probed for pos-
sible copackaging of EED, but no detectable EED3 or
EED4 protein was found in vector particles (not shown).
The lower infectivity of virus samples yielded by EED3/4-
expressing cells was not due to a lower level of cellular
expression and viral incorporation of VSV-G (and Nef,
when Nef was co-expressed in the same cell ; refer to Fig-
ure 6), as the ratios of virus-encapsidated VSV-G to CAp24
and Nef to CAp24 were not significantly different in the
presence or absence of EED3/4 (Fig. 3f and 3g).
We quantitated the EED3+EED4 and Gag contents in plas-
mid-transfected cells, and found that the whole cell con-
tent was in the range of 106  EED and 107  Pr55Gag
molecules per cell at 48 h posttransfection with 1 μg of
pTracer-EED and pNL4-3Luc(R-E-), i.e. a EED:Gag ratio of
1:10. The endogenous EED3+EED4 protein content was
estimated to be ca. 20 to 30 times less, i.e. 3 × 104 to 5 ×
104 EED per cell. Considering that the core of a mature vir-
ion is constituted of 1,400–1,500 Gag molecules [29,30],
we calculated a ratio of 150 molecules of exogenous
EED3/4 per assembling virion in HIV-producing cells.
We next examined whether the negative effect of EED on
virion production reflected or not a lower level of Gag pre-
cursor synthesis. Cells were cotransfected with a constant
amount of pNL4-3Luc(R-E-) and increasing amounts of
either the pTracer-EED or pTracer-Emp plasmid (Fig. 4a).
Gag synthesis was monitored by western blotting showing
the different forms of Gag protein, namely Pr55Gag, the
partially processed products Pr47Gag and Pr41/39, and
CAp25/CAp24. Gag proteins were present in all condi-
tions, and at consistently higher plateau levels in EED3/4-
expressing cells compared to control cells lacking exoge-
nous EED3/4 (Fig. 4b). The EED positive effect on Gag
synthesis occurred in a dose-dependent manner, with a
range of 1.5- to 3-fold for 0.5 to 1 μg of the EED-express-
ing plasmid (Fig. 4c). A similar level of enhancement (2-
to 4-fold with 1 μg of EED plasmid) was observed for luci-
ferase activity in the presence of EED3/4 (Fig. 4d). This
indicated that the negative effect of EED3/4 on virion pro-
duction was not caused by the down-regulation of gag
expression, but probably due to a defect in Gag assembly
and virus production.
Interfering RNA targeting EED increases virion production
To determine whether inhibition of endogenous EED
expression would affect virion production, cells were
transfected with a constant amount of a mixture of pSU-
PER and pSUPER-i-EED at varying ratios of the two plas-
mids. One day later, cells were transfected with pNL4-
3Luc(R-E-) and virion levels determined after a further 48
h-incubation period (Fig. 5a). Since endogenous EED iso-
forms were barely seen on immunoblots (refer to Fig. 1),
the inhibition of EED protein synthesis by pSUPER-i-EED
was monitored in situ by immunofluorescence of trans-
fected cells using anti-EED antibody (Fig. 5b). The
amount of virions produced increased as a function of the
quantity of transfected pSUPER-i-EED and in parallel with
the decrease of the EED signal (Fig. 5b), to reach a maxi-
mum of 4- to 5-fold over the control (Fig. 5c, d). These
results confirmed that EED has a negative effect on virion
production.
Nef antagonizes the negative effect of EED on virus 
production and genome encapsidation
Since Nef forms a complex with EED at the plasma mem-
brane of HIV-1-infected cells, thus contributing to EED
nuclear depletion [13], we wanted to examine the influ-
ence of Nef on the anti-viral activity of EED3/4 (Fig. 6a).
WTNef restored the HIV-Luc infectivity to a level similar to
that obtained in the absence of EED3/4 (Fig. 6b). The N-
myristoylation-negative, packaging-defective mutant
NefG2A showed no significant effect on virus infectivity in
the absence of EED3/4, but when coexpressed with EED3/
4, NefG2A partly restored virus infectivity (Fig. 6b). This
implied that the membrane targeting and encapsidation
of Nef were not absolute prerequisites for the Nef antago-
nistic effect. The deletion mutant NefΔ57, representing
the Nef core [31,32], showed no EED-counteracting activ-
ity (not shown), confirming the assignment of residues
16–35 within the N-terminal domain of Nef as one the
two EED-interacting sites [13].
The production of virions made in the presence Nef and
EED3/4 and their genomic RNA content confirmed the
antagonistic effect of Nef on EED (Fig. 6c–f). With EED
and WTNef, the virion yields were similar to the levels
obtained in the absence of EED3/4 (Fig. 3g and Fig. 6c, d),
and the genome copy number was even slightly higher
(Fig. 6e, f). Of note, the ratio of genome copy number to
virion CAp24 was consistently higher (35–40 %) in viri-
ons produced in the presence of both EED3/4 and WTNef
than that in the presence of WTNef alone, namely 2.86 ±Retrovirology 2007, 4:37 http://www.retrovirology.com/content/4/1/37
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Influence of EED3/4 expression on virus yields Figure 3
Influence of EED3/4 expression on virus yields. (a), Experimental protocol. (b), Virus infectivity. Virions produced by 
293T cells transfected with pTracer-EED (filled symbols) or control pTracer-Emp plasmid (open symbols) were used to infect 
recipient 293T cells, and luciferase expression monitored at different times pi, as indicated. (c, d), Vector titer was determined 
by CAp24 immunoassay (c) or genomic RNA level (d). (e-g), SDS-PAGE polypeptide pattern of virus particles released from 
cells transfected with pTracer-EED (+EED) or control pTracer-Emp plasmid (-EED). Blots were reacted with anti-Gag (e; f, 
bottom panel ; g, bottom panel), anti-VSV-G (f, top panel) and anti-Nef (g, top panel) antibodies. Virus production was signifi-
cantly reduced in the presence of EED, ranging from 20- to 25-fold at 24–48 h posttransfection, based on CAp24 immunoassay 
(c), to 10- to 80-fold, based on genomic RNA levels (d). The Gag protein composition (e), the VSV-G-to-CAp24 (f) and the 
Nef-to-CAp24 (g) ratios did not differ significantly between particles produced in the presence or absence of EED. Note that 
the load of virus samples produced in the presence of EED (e ; +EED) was 5-fold higher than control samples (-EED), and that 
coexpression of Nef restored the virus yields, as shown by CAp24 immunoblotting (g ; bottom panel).
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Gag protein expression in EED3/4-expressing cells Figure 4
Gag protein expression in EED3/4-expressing cells. (a), Experimental protocol. (b, c), Dose-response analysis of EED3/
4 effect on gag gene expression in cells cotransfected with pNL4-3Luc(R-E-) and pTracer-EED (or control pTracer-Emp), at 
varying plasmid inputs (0.25 to 1 μg/106 cells). (b), Autoradiogram of SDS-PAGE and immunoblots reacted with anti-Gag anti-
body and 35SLR-labeled complementary antibody. Band c, 20-kDa cellular protein used as internal control for protein load. (c), 
Histogram of the ratios of total Gag proteins synthesized in the presence of pTracer-EED versus pTracer-Emp. (d), Time-
course analysis of pNL4-3Luc(R-E-)-mediated luciferase expression in 293T cells co-transfected with pTracer-EED (filled sym-
bols) or control pTracer-Emp plasmid (open symbols) at constant plasmid input (1 μg/106 cells). A slight increase in Gag pro-
tein synthesis was detected in the presence of EED, at plasmid inputs higher than 0.5 μg. A similar positive effect of EED (2- to 
5-fold) on luciferase levels was observed between 18 and 72 h posttransfection.
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RNA interference targeting endogenous EED Figure 5
RNA interference targeting endogenous EED. (a), Experimental protocol. 293T cells were transfected with a constant 
amount (3 μg/106cells) of a mixture of pSUPER + pSUPER-i-EED at various ratios of each plasmid, and posttransfected with 
pNL4-3Luc(R-E-) 24 h later. Virus yields were determined in culture medium after a further 48 h incubation. (b) Immunofluo-
rescence (IF) signal of endogenous EED proteins in cells transfected with control pSUPER (upper panel) or pSUPER-i-EED 
(lower panel) at 3 μg/106cells each, and reacted with anti-EED antibody (1:200) and FITC-labeled conjugate(1:320). (c, d), Vir-
ion production was monitored by genomic RNA levels (c), and CAp24 immunoassays (d). Virus production increased in paral-
lel with the decrease of EED signal and as a function of pSUPER-i-EED input, with a maximum of 4- to 5-fold over the control.
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Antagonistic effect of Nef on EED Figure 6
Antagonistic effect of Nef on EED. (a), Experimental protocol. Pelleted HIV-Luc vector particles produced by 293T cells 
transfected with pTracer-EED (filled symbols) or pTracer-Emp (open symbols), with or without Nef protein, WTNef or 
NefG2A mutant, were assayed for (b) vector infectivity, determined by luciferase activity in recipient cells, or (c-f) further 
analyzed by sucrose-D2O gradient ultracentrifugation. Gradient fractions were analyzed for (c, d) CAp24 titer, and (e, f) 
genomic RNA level. WTNef protein counteracted the negative effect of EED, and restored the virus production to control lev-
els.
Gradient fractions
5
10
15
20
25
30
0
5
1
0
1
5
2
0
C
A
p
2
4
,
p
g
/
m
l
(
x
1
0
0
)
1 5 10 15 20
25
20
15
10
5
d
e
n
s
i
t
y
1.25
1.20
1.15
1.10
1.05
w/o EED + WTNef
with EED + WTNef
0
100000
200000
300000
400000
500000
600000
0
5
1
0
1
5
2
0
1 5 10 15 20
w/o EED + WTNef
with EED + WTNef
d
e
n
s
i
t
y
1.25
1.20
1.15
1.10
1.05
G
e
n
o
m
e
c
o
p
y
n
o
.
/
m
l
(
x
1
0
0
)
5E+05
1E+05
3E+05
0
(e)
(c)
0E+00
1E+05
2E+05
3E+05
4E+05
5E+05
0 5 10 15 20
with EED
w/o EED
G
e
n
o
m
e
c
o
p
y
n
o
.
/
m
l
(
x
1
0
0
)
5E+05
3E+05
1E+05
Gradient fractions
0 5 10 15 20
0
w/o EED
with EED 1.25
1.20
1.15
1.10
1.05
d
e
n
s
i
t
y
5
10
15
20
0 5 10 15 20
with EED
w/o EED
Gradient fractions
0 5 10 15 20
C
A
p
2
4
,
p
g
/
m
l
(
x
1
0
0
)
20
w/o EED
with EED
15
10
0
1.25
1.20
1.15
1.10
1.05
d
e
n
s
i
t
y
(d)
(f)
Gradient fractions
(b)
0E+00
1E+05
2E+05
3E+05
4E+05
0 2 04 06 08 0
1E+05
2E+05
3E+05
4E+05
0
time post-infection (h)
0 2 04 06 08 0
L
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y
(
R
L
U
/
1
0
E
6
c
e
l
l
s
)
w/o EED,w/o Nef
w/o EED +WTNef
w/o EED + NefG2A
+ EED + NefG2A
+ EED,w/o Nef
+ EED +WTNef
(a)
Yield & characterization
Pseudotyped
HIV-Luc vector
HIV-Luc
producer cell
+ VSV-G
pNL4-3Luc(R-E-)
Nef
±
pTracer
± EED
§
§
§
§
Infectivity in
recipient cellsRetrovirology 2007, 4:37 http://www.retrovirology.com/content/4/1/37
Page 10 of 19
(page number not for citation purposes)
0.19 × 104 versus 1.87 ± 0.21 × 104 genome copies/pg
CAp24 (m ± SD, n = 4), respectively.
To further dissect the antagonistic effect of Nef on EED,
two other forms of Nef were used, referred to as LAT-Nef
and LATAANef mutant, respectively [26]. Both were fusion
proteins carrying the first 35 amino acids of the linker of
the activated T-cell factor (LAT) at the N-terminus of the
full-length Nef sequence. LATAANef differed from LAT-Nef
by the substitution of the cysteines 26 and 29, which are
palmitoylated, to alanine. Addition of the LAT sequence
was designed in order to target all Nef molecules to lipid
rafts, while LATAANef protein served as the control due to
its cytosolic localization [26]. LAT-Nef showed no EED
antagonistic effect, whereas LATAANef behaved as WTNef
in terms of virion yields (Fig. 7). This confirmed that
membrane targeting was not required for the anti-EED
function of Nef, and suggested that the anti-EED function
of Nef involved a subset of Nef molecules which were not
localized in the lipid rafts. The next experiments examined
whether the negative effect of EED on Gag assembly and
the antagonistic effect of WTNef, NefG2A and LATAANef
proteins on EED were associated with alterations of pro-
tein compartmentalization.
Influence of Nef on the cellular distribution of EED
Cells cotransfected with pNL4-3Luc(R-E-), pTracer-EED
(or pTracer-Emp), with or without Nef, were fractionated
into cytosolic fraction (C), membrane compartment (M)
and insoluble pellet (P) (Fig. 8a), and each fraction
probed for Gag, EED and Nef proteins. As expected, Gag
polyprotein precursor and maturation products were
mainly detected in fractions M and P, and in small
amounts in cytosol (Fig. 8b ; left panel). Expression of
EED3/4 did not significantly change the distribution of
Gag between the three compartments (Fig. 8b ; right
panel). Exogenous EED3/4 proteins were found in all
three compartments, with a predominance in the mem-
brane fraction M (Fig. 8c, right panel), as were the endog-
enous EED's (Fig. 8c, left panel). Further fractionation of
the M compartment showed that the membrane domains
where EED localized were different from the lipid rafts
(Fig. 8d). WTNef protein was recovered in majority in
fraction M, but upon EED3/4 coexpression, we observed
an apparent Nef depletion from the M compartment and
its relocation to the insoluble fraction P (Fig. 8e). The
same change in the EED pattern was observed in the pres-
ence of WTNef, with relocation of EED to fraction P (Fig.
8f). EED relocation in fraction P also occurred in the pres-
ence of NefG2A or LATAANef, but not with the deletion
mutant NefΔ57 (cytosolic) or LAT-Nef (lipid raft-tar-
geted) (Fig. 8f).
Immunofluorescence (IF) analysis confirmed the cell frac-
tionation patterns, and showed the absence of co-localiza-
tion of EED and LAT-Nef proteins. On the contrary, the
EED and WTNef signals co-localized in the cytoplasmic
compartment (Fig. 9). Likewise, co-localization occurred
for EED and NefG2A proteins, and the IF pattern sug-
gested that they co-localized in large intracytoplasmic
inclusions (Fig. 9e).
Electron microscopy
Electron microscopic analyses were carried out using 293T
cells cotransfected with pNL4-3Luc(R-E-) and pTracer-
Emp (Fig. 10a, and inset a') or pTracer-EED (Fig. 10 b–f).
A number of HIV-1 virion particles were seen budding at
the surface of control cells (Fig. 10, see inset a' where an
intermediate step of budding and egress was observed).
Upon EED3/4 expression, only rare cells exhibited bud-
ding events at the plasma membrane. Interestingly, sev-
eral clusters of nuclear pore complexes were found in the
cytoplasm, at distance from the nuclear envelope (Fig.
10b; arrows). Enlargement of cytoplasmic areas from
EED3/4-expressing cells showed clusters of nuclear pore
complexes viewed in tangential (Fig. 10b, c) or transversal
section (Fig. 10d, e), and associated with bundles of fila-
ments [see Additional files 1 and 2]. The cytoplasmic
compartment of EED3/4-expressing cells also showed an
abundant vesicular network. At higher magnification, we
frequently observed a local thickening of the vesicular
membrane and irregular protrusions into the lumen, rem-
iniscent of intracisternal budding of virus or virus-like par-
ticles (Fig. 10f). These results further confirmed that EED
impacted on HIV-1 assembly and release.
Discussion
In the present study, we found that overexpression of
human EED3/4, a member of the PcG proteins, resulted in
a global anti-HIV-1 effect. At early steps of infection,
EED3/4 had a modest negative impact on incoming HIV-
Luc virions (2- to 3-fold at best; Fig. 2), in comparison
with that caused by known cellular restriction factors [33-
36]. The limited negative effect caused by EED394, a
mutant defective in MA binding [11], suggested that this
relied on the integrity of EED-MA interaction. At the late
phase of the virus life cycle, EED exerted a significant neg-
ative effect on virion production by EED3/4-expressing
cells, with 10- to 80-fold lower virus yields (Fig. 3). This
effect was not due to an EED-mediated negative effect on
Gag protein synthesis, since higher levels of Gag protein,
as well as the reporter gene product luciferase, were pro-
duced by EED-expressing cells (Fig. 4).
Quantification of the intracellular content of EED and
Gag showed a ratio of 1 to 10 in terms of EED3/4 to Gag
proteins, which corresponded to approximately 150 cop-
ies of EED3/4 proteins available per virus particle contain-
ing 1,500 Gag molecules [29,30]. EED proteins are crucial
epigenetic regulators, and several published reports indi-Retrovirology 2007, 4:37 http://www.retrovirology.com/content/4/1/37
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Effect of Nef mutants on EED Figure 7
Effect of Nef mutants on EED. (a), Experimental protocol. HIV-Luc virions were produced by 293T cells transfected with 
pTracer-EED or pTracer-Emp, in the presence of various Nef proteins, WTNef, NefΔ57 mutant, or fusion constructs LAT-Nef 
or LATAA-Nef. Cell culture fluids were centrifuged and the amounts of virions in pellets quantified by genomic RNA levels. (b), 
Histogram of virion production in the presence of Nef without EED (grey bars) or EED with Nef (filled bars). (c), Ratio of virus 
yields in the presence versus the absence of EED, expressed as percentage. WTNef and LATAA-Nef showed the same EED 
antagonistic effect, whereas LAT-Nef and NefΔ57 mutants had a different phenotype.
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Cellular distribution of EED3/4 upon NEF expression Figure 8
Cellular distribution of EED3/4 upon NEF expression. (a), Experimental protocol. Cells were cotransfected with pNL4-
3Luc(R-E-) and pTracer-EED (or pTracer-Emp), with or without coexpression of various Nef proteins, WTNef or NefG2A 
and NefΔ57 mutants, or fusion constructs LAT-Nef or LATAA-Nef, as indicated on top of each panel. Cells were fractionated 
into cytosolic supernatant (C), membrane fraction (M) and insoluble pellet (P), as shown in panels (b),(c),(e) and (f). Fractions 
were probed for (b) Gag, (c, d, f) EED, (e) Nef, and (d) CD55. (d), Isolation of lipid rafts by ultracentrifugation of flotation. 
Gradient fractions were analyzed by SDS-PAGE and immunoblotting, using anti-CD55 antibodies (detected by phosphatase-
labeled complementary antibody) and anti-EED antibodies (detected by peroxidase-labeled complementary antibody). (m), Pro-
tein markers, with molecular masses indicated in kDa. Bands of exogenous EED3 and EED4 isoforms are indicated by black 
dots. Note that EED did not cosediment with lipid rafts, identified by the CD55 marker. Coexpression of EED and WTNef, 
NefG2A or LATAA-Nef, but not NefΔ57 or LAT-Nef, resulted in the relocation of EED and Nef proteins in a cellular compart-
ment recovered as pelletable fraction (P).
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Confocal fluorescence microscopy of 293T cells expressing EED alone (a) or WTNef alone (b), or co-expressing EED and var- ious Nef proteins; (c),WTNef ;(d),LAT-Nef ;(e), NefG2A. Figure 9
Confocal fluorescence microscopy of 293T cells expressing EED alone (a) or WTNef alone (b), or co-express-
ing EED and various Nef proteins; (c),WTNef ;(d),LAT-Nef ;(e), NefG2A. The experimental protocol was as 
described in Fig. 8a. Left panels: anti-EED rabbit antibody and Alexa Fluor® 488-labeled goat anti-rabbit IgG ; middle panels: 
anti-Nef mAb and Alexa Fluor® 633-labeled goat anti-mouse IgG antibody; right panels: merged images. Note the absence of 
co-localization of EED and LAT-Nef, contrasting with the co-localization signals of EED and WTNef or NefG2A.Retrovirology 2007, 4:37 http://www.retrovirology.com/content/4/1/37
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Electron microscopic analysis of 293T cells cotransfected with pNL4-3Luc(R-E-) and pTracer-Emp (a, and inset a') or pTracer- EED (b-f) at 3 μg each plasmid per 2 × 106 cell sample, and harvested at 48 h posttransfection Figure 10
Electron microscopic analysis of 293T cells cotransfected with pNL4-3Luc(R-E-) and pTracer-Emp (a, and inset 
a') or pTracer-EED (b-f) at 3 μg each plasmid per 2 × 106 cell sample, and harvested at 48 h posttransfection. 
(a), Control cells without exogenous EED expression. Note the number of viral particles budding at the cell surface. Inset (a'), 
Enlargement of one virus particle at an intermediate step of budding and egress. (b), EED3/4-expressing cells showing very 
rare budding events at the plasma membrane. Several clusters of ringlike structures (arrows) were observed in the cytoplasm, 
at distance from the nuclear envelope. Their dimensions (70–80 nm in overall diameter) and constitutive elements (electron-
dense annular granules of 15–18 nm in diameter and central channel of 25–27 nm) were characteristic of nuclear pore com-
plexes. (c-f), Enlargement of cytoplasmic areas from EED3/4-expressing cells showing clusters of nuclear pores (NP), viewed in 
tangential (c) or transversal (d, e) section, and in association with filaments arranged in bundles (F). (f), Cytoplasmic area of 
EED3/4-expressing cell showing intracytoplasmic vesicles at higher magnification. Note the local thickening of the vesicular 
membrane and the intraluminal budding of virus-like particles. N, nucleus ; C, cytoplasm ; M, mitochondria.
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cated that EED regulation depended on multiple context-
sensitive  PcG complexes rather than gene dosage
[15,17,18]. In addition, EED protein content has been
found to vary among cell types [17]. Our results on EED-
to-Gag stoichiometry in HIV-1 producer HEK-293T cells
did not allow us to assess whether the biological effects of
EED on HIV-1 replication were due to (i) a gene dosage
effect or (ii) a wrong balance between EED isoforms and
EED-containing complexes, e.g. EED3 + EED4 versus
EED1 + EED2, or (iii) both. However, the observation that
EED3 and EED4 isoforms preferentially localized in PRC3
complexes [23], and that HEK-293 epithelial cells had a
high content of PRC1 and PRC2 proteins, compared to
other epithelial cells such as HeLa [17], would be in favor
of the second hypothesis.
Some clue to the cellular mechanism(s) of EED-mediated
negative effect on virus yields was provided by our EM
analysis of pTracer-EED- and pNL4-3Luc(R-E-)-cotrans-
fected cells: cytoplasmic clusters of nuclear pore com-
plexes in association with filament bundles reminiscent of
annulate lamellae were observed in numbers in EED-
expressing cells, and not in control cells (Fig. 10). Neofor-
mation, ectopic localization or aberrant assembly of
annulate lamellae and nuclear pore complexes (NPC)
have already been described, in particular in malignant
cells [37,38], fertilization-arrested human oocytes [39],
certain virus-infected cells [40], and cells overexpressing
the nuclear envelope pore membrane protein POM121
[41]. We hypothesized that exogenous EED3/4 mimicked
the POM121 effect of recruitment of NPC proteins in
ectopic nucleation sites [41] and provoked the aberrant
assembly of NPC substructures within the cytoplasm,
resulting in a sequestration or/and mistrafficking of viral
genomic RNA (gRNA) or gRNA/Gag complexes and their
failure to reach the virion assembly sites [42,43]. Our
experimental results and hypothesis were compatible
with the properties of EED proteins which shuttled
between the nuclear and plasma membrane compart-
ments [8], and interacted with NPC [12]. Thus, EED
would be a restriction factor interfering with HIV-1 repli-
cation mostly at the level of virion production, and via dif-
ferent and nonexclusive mechanisms. Due to its
interference with gRNA trafficking, EED would have an
indirect negative impact on genome packaging and virus
assembly. The negative effect of EED on genome packag-
ing and virus assembly could also be mediated by interac-
tions of EED with genome ends [13], and viral proteins
MA and/or IN [11,12].
WTNef and NefG2A, but not the NefΔ57 mutant nor the
lipid raft-targeted fusion LAT-Nef, restored virus produc-
tion and infectivity to levels observed in the absence of
EED (Fig. 6 and 7). This indicated that the EED-counter-
acting activity of Nef did not depend on its N-myristoyla-
tion and its virus packaging (abolished in NefG2A), but
required its N-terminal domain, deleted from the NefΔ57
mutant. This confirmed the mapping of the EED-binding
site to residues 16–35 in the N-terminal domain of Nef,
although a second EED-binding region has been identi-
fied in the C-terminal domain [13]. This region over-
lapped the ED/EE motif identified as the v-ATPase
binding site at position 174–175 in Nef, and was essential
for plasma membrane recruitment of EED [13]. However,
our experimental data with the NefΔ57 mutant suggested
that the C-terminal EED-binding domain of Nef alone
was not sufficient to reverse the negative effect of EED on
virus yields. The fusion protein mutant LATAANef, which
lacked the lipid raft targeting function [26], showed the
same phenotype as WTNef and NefG2A in terms of EED
antagonistic effect (Fig. 7 and 8). This implied that the
subset of Nef molecules localized in the lipid rafts did not
contribute to the EED counteracting effect, and that the
cellular compartment in which Nef bound and seques-
tered EED was different from the lipid rafts.
Interestingly, the WTNef-mediated positive effect on
infectivity was more pronounced when vectors were pro-
duced in the presence of EED3/4, and was associated with
a slight but consistent higher mean genome content per
particle (Fig. 6). This cooperative effect between Nef and
EED suggested the involvement of other cellular compart-
ments or/and factors in virus production and infectivity. A
recent study has shown the facilitation of HIV-1 egress
mediated by Nef-AIP1 interactions, via their positive effect
on multivesicular body (MVB) proliferation [46]. Alterna-
tively, EED-Nef complexes might trap cellular factor(s)
which negatively interfere(s) with virus assembly and viral
genome incorporation, depleting them from the assembly
sites. Nef might also compete for EED binding with cer-
tain cellular protein(s) which positively affect(s) the virus
egress. In the two latter hypotheses, plasma membrane
integrins, identified as partners of EED [8], might repre-
sent good candidates, since integrins are connected to tet-
raspanin-enriched microdomains (TEMs), and since
TEMs represent potential gateways for HIV-1 egress [47].
The nature and mechanism of the Nef-mediated EED relo-
cation are presently under investigation in other cells than
the HEK-293T cell line.
Methods
DNA constructs
EED
For simultaneous expression of wild type (WT) EED3 and
EED4 proteins in mammalian cells, the eed gene sequence
from M95 to R535, as aligned with the mouse EED
sequence of 535 residues [7], with a stop codon after the
C-terminal residue (EED441 ; [12]), was cloned into the
EcoR I and Not I sites of the expression plasmid pTracer™-
EF/Bsd (version B ; Invitrogen). pTracer™-EF/Bsd was cho-Retrovirology 2007, 4:37 http://www.retrovirology.com/content/4/1/37
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sen to provide GFP protein for visual detection of trans-
fected cells, as well as two C-terminal tags, V5 epitope and
oligo-histidine. However, since the C-terminal extension
of 30 residues could alter the biological properties of EED
in one or the other way, we introduced a stop codon after
the C-terminus of EED in pTracer-EED, to obtain
untagged EED3/4 isoforms. The resulting plasmid was
abbreviated pTracer-EED, and the control empty plasmid
was referred to as pTracer-Emp. Plasmid pTracer-EED394
harbored the EED mutant ST394AI, defective in HIV-1 MA
binding [11]. Plasmid pcDNA3-EED441 consisted of the
EED441-coding sequence cloned into pcDNA3.
Nef
Plasmids expressing the different Nef proteins were
obtained from D. Rekosh and M.-L. Hammarskjöld (Uni-
versity of Virginia at Charlottesville). WTNef was
expressed using pHR1405 (pCMV-nef  plasmid), which
contained the full-length WT nef sequence from pNL4-3
under the control of the simian cytomegalovirus (CMV)
IE94 gene promoter-enhancer [48], pHR1864 expressed
the G-to-A substitution mutant (NefG2A), and pHR1871
the N-terminal deletion mutant NefΔ57 corresponding to
the Nef core. Plasmids pHR2458 and pHR2462 encoded
LAT and LAT mutant fusion proteins LAT-Nef and
LATAANef, respectively [26].
HIV-1-Luc vector
Plasmid phCMV-G encoded the vesicular stomatitis virus
glycoprotein G under the control of the human CMV pro-
moter with rabbit β-globin intron II and polyadenylation
sequence [49]. Plasmid pNL4-3Luc(R-E-) [50] carried the
firefly luciferase reporter gene (luc) in lieu of the deleted
nef gene, and two frame-shift mutations in vpr and env
genes.
Cells and cell fractionation
Human embryonic kidney cells HEK-293T were grown in
Dulbecco's modified glutamine-containing Eagle
medium (Gibco), supplemented with antibiotics and 10
% fetal calf serum. For cell fractionation, 293T cells were
lysed by three cycles of freezing and thawing in Tris-buff-
ered saline (TBS), and lysates centrifuged at 8,000 × g for
10 min at 4°C. The supernatant (C1) was spared, and the
first pellet (P1) was resuspended in TBS and subjected to
a second round of centrifugation in the same conditions,
giving supernatant C2 and intermediate pellet P2. Super-
natants C1 and C2, corresponding to the cytosolic frac-
tion, were pooled and abbreviated (C). Pellet P2 was then
resuspended in TBS containing 0.5 % Triton X-100 for 30
min at 37°C, and centrifuged at 8,000 × g for 10 min at
4°C. The supernatant corresponded to Triton-soluble
membrane fraction (M) comprising lipid rafts and non-
rafts domains, and the final pellet (P) contained nuclei
and cell organelles. For isolation of lipid rafts, cell lysates
(ca. 1 ml) in HNE buffer (150 mM NaCl, 1 mM Na2EDTA,
25 mM HEPES, pH 6.5) containing a protease inhibitor
cocktail (Boehringer) and 1 % Triton X-100 were mixed
with an equal volume of 80 % sucrose, and overlaid with
two layers of sucrose solution in HNE, 30 % (6 ml) and 5
% sucrose (4 ml), respectively. Samples were subjected to
ultracentrifugation of flotation in a Beckman SW41 rotor
for 18 h at 39 krpm and 4°C [51]. Anti-CD55 polyclonal
antibody (H-319 ; Santa Cruz Biotechnology, Inc.) was
used to detect the lipid rafts marker CD55.
Gel electrophoresis, antibodies and immunoblotting
Polyacrylamide gel electrophoresis of SDS-denatured pro-
tein samples (SDS-PAGE), and immunoblotting analysis
have been previously described [52,53]. Anti-HIV-1 Gag
protein and anti-EED441-H6 protein rabbit antisera were
laboratory-made [12,54]. Mouse monoclonal antibody
(mAb) anti-CAp24 (Epiclone #5001) was purchased from
Cylex Inc. (Columbia, MD), and anti-EED mAb (clone
M26) was obtained from A. Otte (BioCentrum, Amster-
dam). M26 has been raised against the N-terminal
domain of the EED molecule, comprising of residues 95–
174 [55]. Anti-HIV-1 reverse transcriptase (RT) mAb
(clone 8C4D7; IgG1) was purchased from Intracell
(Issaquah, WA). MAb anti-HIV-1 Nef C-terminal domain
was obtained from Transgene SA (MATG-0020 ; Stras-
bourg, France) and had its epitope mapped to residues
161–175 [56]. MAb anti-VSV-G glycoprotein (clone
P5D4) was purchased from Sigma. When needed, His-
tagged proteins were detected using monoclonal anti-
HisTag antibody (Qiagen) specific for N-, C-terminal and
internal histidine clusters. Phosphatase-labeled anti-rab-
bit or mouse IgG conjugates were purchased from Sigma.
For luminograms, chemiluminescent peroxidase substrate
Supersignal™ (Pierce) was used. Immunological quantifi-
cation of membrane-transferred proteins was performed
by radio-immunoblotting [54], using 35SLR-labeled anti-
rabbit or anti-mouse IgG antibody (Amersham Bio-
sciences; 2,000 Ci/mmol; 10 μCi per 100 cm2 membrane).
Autoradiograms were scanned and quantitated by densit-
ometric analysis, or alternatively, protein bands were
excised from blots and radioactivity measured in a liquid
scintillation spectrometer (Beckman LS-6500). Quantifi-
cation of exogenous proteins in lysates from transfected
cells was performed by scanning Coomassie Blue-stained
SDS-PAGE gels. Protein content in EED or Pr55Gag bands
was estimated by comparison with a range of BSA concen-
trations, after subtraction of the background signal from
control cells.
Production of HIV-Luc vector
VSV-G-pseudotyped HIV-1 competent for a single round
of replication and carrying the luc gene was produced by
cotransfection of 293T cells (producer cells) with phCMV-
G and pNL4-3Luc(R-E-) at 10 μg each per 7 × 106 to 10 ×Retrovirology 2007, 4:37 http://www.retrovirology.com/content/4/1/37
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106  cells in standard experiments, with or without
pTracer-EED or pTracer-Emp, using lipofectamine™ and
Plus™ Reagent (Invitrogen) as transfecting agents. The cell
culture supernatant containing the VSV-G pseudotyped
HIV (abbreviated HIV-Luc) was collected at 48 h post-
transfection, aliquoted and used for the infection of recip-
ient 293T cells. HIV-Luc titers were determined by CAp24-
antigen enzyme-immunoassay (VIDAS® HIV P24 II test ;
bioMérieux®  SA, Marcy-l'Etoile, France ; [57]), and
expressed as CAp24 concentration (in pg/ml). Genomic
RNA content of virions or cells was determined using an
automated ribonucleic acid isolation technique [58,59]
adapted to the NucliSens EasyMag™ Extractor
(bioMérieux® SA), and a real-time, isothermic gene ampli-
fication method (nucleic acid sequence based amplifica-
tion or NASBA® ; [60]) with the NucliSens®EasyQ HIV-1
v1.1 kit (NucliSens®EasyQ platform; bioMérieux®  SA).
Results were expressed as the number of genome copies/
106 cells for cell lysates, and genome copies/ml for cell
culture supernatants containing virus particles.
Isolation of HIV-Luc virions
Two different methods of purification were used. (i) Iso-
pycnic gradient centrifugation[54]. Virus particles released
in the extracellular medium were analyzed by ultracentrif-
ugation in sucrose-D2O gradients. Linear gradients (10-ml
total volume, 30–50 %, w:v) were centrifuged for 18 h at
28 krpm in a Beckman SW41 rotor. The 50 % sucrose
solution was made in D2O buffered to pH 7.2 with
NaOH, and the 30 % sucrose solution was made in 10
mM Tris-HCl, pH 7.2, 150 mM NaCl, 5.7 mM Na2EDTA.
Aliquots of 0.4 ml were collected from the top. (ii)
Sucrose-step gradient centrifugation [61]. Cell culture super-
natants were clarified by low-speed centrifugation, and
virions recovered by pelleting through a sucrose cushion
(20% in phosphate-buffered saline) at 30 krpm for 1 h at
15°C in a Kontron TST55.5 rotor.
Functional assays for EED
(i) Effect on incoming virions
Single-round replication assays of VSV-G-pseudotyped
HIV-Luc were performed in the absence (pTracer-Emp) or
presence of exogenous EED3/4 proteins (pTracer-EED).
Aliquots of recipient 293T cells were transfected with
equal amounts of pTracer-EED or pTracer-Emp (1 μg/106
cells), or with plasmid inputs varying from 0 to 5 μg/106
cells. 24 h later, they were infected with HIV-Luc vector, at
multiplicities of infection ranging from 20 to 80 ng
CAp24 per 106 cells. Luciferase activity was measured at
different times post-infection (pi) as previously described
[62].
(ii) Effect on virus production
293T cells (2 × 106 cells) were cotransfected with 2 μg each
of pNL4-3Luc(R-E-), phCMV-G, pTracer-EED (or pTracer-
Emp), with or without Nef-expressing plasmid. Culture
supernatants were collected at different times posttrans-
fection, and assayed for exogenous RT activity [63,64],
CAp24 titer, genomic RNA level and infectivity measured
by luciferase assays on naive recipient 293T cells, as
described above.
RNA interference (siRNA)
Expression of short interfering RNA (siRNA) in 293T cells
was performed using the pSUPER plasmid [65]. The insert
in pSUPER (a gift from Dr. R. Agami [65]) was designed
to express a 19 nt-long RNA sequence (AGCACTATGTT-
GGCCATGG) that has been identified as the most effi-
cient oligonucleotide to target EED [66]. The resulting
plasmid was referred to as pSUPER-i-EED. Cells were
transfected with constant amounts (3 μg/106cells) of a
mixture of pSUPER + pSUPER-i-EED at various ratios of
each plasmid, and 24 h later the cells were transfected
with with pNL4-3Luc(R-E-). Virions were pelleted at 48 h
posttransfection, and virus yields determined by viral
genomic RNA level and CAp24 immunoassays.
Cellular imaging
Confocal immunofluorescence microscopy
Cell monolayers were harvested at 48 h posttransfection,
fixed with 2 % paraformaldehyde in phosphate buffered
saline (PBS) and permeabilized in 0.2 % Triton X100 in
PBS. Cells were blocked with 1% BSA in PBS (PBS-BSA),
and reacted with rabbit anti-EED antibody (laboratory-
made ; 1:200 in PBS-BSA) and Alexa Fluor® 488-labeled
goat anti-rabbit IgG (Molecular Probes, Invitrogen), or
mAb anti-Nef (USBiological H6004-15C ; epitope aa168-
174 ; 1:200 in PBS-BSA) and Alexa Fluor® 633-labeled goat
anti-mouse IgG antibody (Molecular Probes, Invitrogen).
Samples were postincubated with DAPI and mounted on
slides. Observations by confocal fluorescence microscopy
were performed using a Leica TCS SP2 confocal micro-
scope.
Electron microscopy (EM)
Cells harvested at 48 h posttransfection were pelleted,
fixed with 2.5% glutaraldehyde in 0.1 M phosphate
buffer, pH 7.5, post-fixed with osmium tetroxide (2 % in
H20) and treated with 0.5% tannic acid solution in H20.
The specimens were dehydrated and embedded in Epon
(Epon-812; Fulham, Latham, NY). Sections were stained
with 2.6 % alkaline lead citrate and 0.5 % uranyl acetate
in 50 % ethanol, and post-stained with 0.5% uranyl ace-
tate solution in H20 [12,67]. Specimens were examined
under a Jeol 1200-EX electron microscope, equipped with
a MegaView II high resolution TEM camera and a Soft
Imaging System of analysis (Eloïse, Roissy, France). About
150 independent cell sections (10 to 12 separate fields of
10 to 15 cells each) were examined under the electron
microscope.Retrovirology 2007, 4:37 http://www.retrovirology.com/content/4/1/37
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